ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
January 07, 2021Windtree Therapeutics, Inc. announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). -
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company
December 24, 2018Windtree Therapeutics, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and CVie Investments Limited (CVie).....
Pharma Sources Insight January 2025
